Physician profile
Eli T James
NPI 1669959441
$1,530.90
in general payments reported to CMS, 2019-2025
20 companies · $211 in 2025
The $211 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $165 · 2021: $61.79 · 2022: $341 · 2023: $302 · 2024: $451 · 2025: $211.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $963.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $963.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $228.74 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $198.89 | 2021-2025 | Jardiance, Spiriva Respimat |
| Abbvie INC. | $166.87 | 2022-2024 | |
| Lilly USA, LLC | $91.65 | 2023-2024 | Mounjaro |
| Janssen Pharmaceuticals, INC | $87.90 | 2021-2024 | Xarelto |
| Celgene Corporation | $86.23 | 2019 | |
| Lundbeck LLC | $84.01 | 2024-2025 | Rexulti, Brintellix |
| Astellas Pharma US INC | $81.83 | 2022-2024 | Veozah, Myrbetriq |
| Amgen INC. | $77.61 | 2022-2024 | Evenity, Prolia |
| Dexcom, INC. | $61.31 | 2022-2025 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $54.22 | 2022 | |
| Merck Sharp & Dohme LLC | $53.08 | 2019-2021 | |
| Novo Nordisk INC | $50.64 | 2022-2024 | Rybelsus, Ozempic |
| Myriad Women'S Health, INC. | $43.78 | 2023 | Myrisk |
| Glaxosmithkline, LLC. | $37.13 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $36.31 | 2025 | Caplyta |
| Sanofi Pasteur INC. | $33.13 | 2022 | |
| Organogenesis INC. | $25.19 | 2021 | |
| Xeris Pharmaceuticals, INC. | $18.46 | 2024 | Gvoke Hypopen |
| Kowa Pharmaceuticals America, INC. | $13.92 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eli James listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.